XML 79 R54.htm IDEA: XBRL DOCUMENT
v3.25.0.1

SEGMENT INFORMATION (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
Schedule of Information About Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income | The table below presents information about Edwards Lifesciences' reportable segments (in millions):
| Years Ended December 31,
| 2024 |  | 2023 |  | 2022
Segment Net Sales |  |  |  |  |
United States | $ | 3,206.0 |  |  | $ | 2,947.9 |  |  | $ | 2,628.2 |
Europe | 1,321.7 |  |  | 1,180.2 |  |  | 1,040.3 |
Japan | 339.8 |  |  | 350.8 |  |  | 359.5 |
Rest of World | 572.0 |  |  | 531.1 |  |  | 436.0 |
Total segment net sales | $ | 5,439.5 |  |  | $ | 5,010.0 |  |  | $ | 4,464.0 |
Cost of Sales |  |  |  |  |
United States | $ | 546.6 |  |  | $ | 505.2 |  |  | $ | 418.9 |
Europe | 299.1 |  |  | 268.5 |  |  | 237.9 |
Japan | 48.1 |  |  | 46.6 |  |  | 41.5 |
Rest of World | 158.1 |  |  | 136.2 |  |  | 118.2 |
Total segment cost of sales | $ | 1,051.9 |  |  | $ | 956.5 |  |  | $ | 816.5 |
Selling, general, and administrative expenses |  |  |  |  |
United States | $ | 498.0 |  |  | $ | 432.8 |  |  | $ | 340.7 |
Europe | 282.6 |  |  | 260.6 |  |  | 233.0 |
Japan | 85.1 |  |  | 70.1 |  |  | 77.4 |
Rest of World | 181.4 |  |  | 166.4 |  |  | 142.6 |
Total segment selling, general, and administrative expenses | $ | 1,047.1 |  |  | $ | 929.9 |  |  | $ | 793.7 |
Other Segment Items |  |  |  |  |
United States | $ | 2.4 |  |  | $ | 2.1 |  |  | $ | 4.8 |
Europe | 14.9 |  |  | (4.0) |  |  | (34.9) |
Japan | (6.8) |  |  | 21.3 |  |  | (58.1) |
Rest of World | (10.5) |  |  | (0.5) |  |  | (1.9) |
Total other segment items (a) | $ | — |  |  | $ | 18.9 |  |  | $ | (90.1) |
Segment Operating Income |  |  |  |  |
United States | $ | 2,159.0 |  |  | $ | 2,007.8 |  |  | $ | 1,863.8 |
Europe | 725.1 |  |  | 655.1 |  |  | 604.3 |
Japan | 213.4 |  |  | 212.8 |  |  | 298.7 |
Rest of World | 243.0 |  |  | 229.0 |  |  | 177.1 |
Total segment operating income | $ | 3,340.5 |  |  | $ | 3,104.7 |  |  | $ | 2,943.9 |
_______________________________________________________________________________ (a) Other segment items include research and development expenses and foreign currency.
| Years Ended December 31,
| 2024 |  | 2023 |  | 2022
Pre-tax Income Reconciliation |  |  |  |  |
Segment operating income | $ | 3,340.5 |  |  | $ | 3,104.7 |  |  | $ | 2,943.9 |
Unallocated amounts: |  |  |  |  |
Corporate items | (1,886.8) |  |  | (1,684.4) |  |  | (1,504.2) |
Restructuring charges, separation costs, and other | (61.0) |  |  | — |  |  | (60.7) |
Intellectual property agreement and certain litigation expenses | (40.4) |  |  | (203.5) |  |  | (15.8) |
Change in fair value of contingent consideration liabilities | — |  |  | 26.2 |  |  | 35.8 |
Foreign currency | 26.4 |  |  | 65.9 |  |  | 99.4 |
Consolidated operating income | $ | 1,378.7 |  |  | $ | 1,308.9 |  |  | $ | 1,498.4 |
Non-operating income | 169.4 |  |  | 63.5 |  |  | 21.1 |
Consolidated pre-tax income | $ | 1,548.1 |  |  | $ | 1,372.4 |  |  | $ | 1,519.5 |
Schedule of Enterprise-Wide Information | Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated financial statements. Refer to the segment information above for United States net sales for the years ended December 31, 2024, 2023, and 2022. Sales within any other individual country were less than 10 percent of the Company's consolidated net sales in each of those years.
| As of or for the Years Ended December 31,
| 2024 |  | 2023 |  | 2022
Net Sales by Major Product Group |  |  |  |  |
Transcatheter Aortic Valve Replacement | $ | 4,106.1 |  |  | $ | 3,879.8 |  |  | $ | 3,518.2 |
Transcatheter Mitral and Tricuspid Therapies | 352.1 |  |  | 197.6 |  |  | 116.1 |
Surgical Structural Heart | 981.3 |  |  | 932.6 |  |  | 829.7 |
| $ | 5,439.5 |  |  | $ | 5,010.0 |  |  | $ | 4,464.0 |
Long-lived Tangible Assets by Geographic Region |  |  |  |  |
United States | $ | 1,249.6 |  |  | $ | 1,186.9 |  |  | $ | 1,113.3 |
Other countries | 534.6 |  | 488.5 |  | 457.0
| $ | 1,784.2 |  |  | $ | 1,675.4 |  |  | $ | 1,570.3 |

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration